It is the second company to join this BME market in 2022 and debuts with a market value of 12.24 million euros
The Board of Directors of BME Growth has approved the listing of VYTRUS BIOTECH, after it received the favourable assessment report on its listing from the Coordination and Admission Committee.
VYTRUS BIOTECH is the second company to join this BME Market so far this year. It will start trading on 15 March and to mark the occasion a bell ringing will be held in the Barcelona stock exchange.
The company's Board of Directors has set a reference value for each of its shares of 1.72 euros, giving the company a total valuation of 12.24 million euros.
The company’s ticker symbol will be “VYT”. The company’s Registered Advisor and Liquidity Provider is GVC Gaesco Valores.
VYTRUS BIOTECH bases its activity on plant stem cell culture technology for the development, production and commercialisation of high added value active ingredients in the cosmetic sector. The company’s staff is made up of near 30 people in its facilities in Terrassa (Barcelona) and it is present in Europe, USA, LATAM and Asia through its international network of distributors.
The Informative Document on VYTRUS BIOTECH can be found on BME Growth’s website and contains all the relevant information on the company and its business.